GET DAILY SIGNALSCapsoVision (CV) Q3 2026: Modest Revenue Growth Amid AI Highlights Launch
Key Takeaways
- CapsoVision reported third-quarter 2026 revenue of $3.568 million, up 0.8% from $3.538 million in the prior-year quarter.
- Net loss narrowed to $7.339 million, or $0.15 per share, compared with a loss of $7.921 million, or $0.17 per share, a year earlier.
- Both revenue and earnings per share (EPS, a measure of profit or loss divided by shares outstanding) came in modestly below analyst consensus estimates.
- The company's AI Highlights feature for its CapsoCam Plus capsule received U.S. Food and Drug Administration (FDA) clearance in late September and launched commercially on November 2.
- Gross margin declined to 49% from 54% a year earlier, while operating expenses fell roughly 8% year over year.
- Cash and cash equivalents stood at $21.8 million as of September 30, 2026, following an $18 million registered direct offering.
Why This Quarter Matters
CapsoVision (CV) is a commercial-stage medical technology company focused on capsule endoscopy and AI-enabled gastrointestinal imaging. Its third-quarter 2026 report matters because it arrives at a pivotal moment: the company has just secured FDA clearance for its AI Highlights software and launched it in the U.S., while simultaneously completing enrollment for the clinical study supporting its planned CapsoCam Colon submission. Investors are watching whether these regulatory and product milestones can translate into accelerating revenue after several quarters of comparatively slow top-line growth. The quarter also reflects how effectively management is balancing investment in its pipeline against cost discipline and a still-narrowing bottom line. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Numbers Behind the Quarter
For the third quarter ended September 30, 2026, CapsoVision reported revenue of $3.568 million, a 0.8% increase from $3.538 million in the same period last year. Analysts had expected roughly $3.759 million, so the top line fell slightly short of consensus.
The company posted a net loss of $7.339 million, or $0.15 per share, compared with a net loss of $7.921 million, or $0.17 per share, a year earlier. The reported loss per share was modestly wider than the roughly $0.14 consensus estimate. Gross profit was $1.8 million, with gross margin at 49%, down from 54% in the prior-year quarter, reflecting higher material costs and inventory-related charges. Operating expenses declined to $9.1 million from $9.9 million, an approximately 8% reduction.
The company shipped 8,464 CapsoCam Plus capsules during the quarter, up 1.5% from 8,336 a year earlier, and more than 184,000 patients worldwide have now used the device. CapsoVision strengthened its balance sheet with an $18 million registered direct offering generating roughly $17.8 million in net proceeds, plus about $1.7 million raised through its at-the-market (ATM) program. Cash and cash equivalents totaled $21.8 million at quarter-end.
How the Market Responded
The market response to CapsoVision's third-quarter report was relatively muted. Following the release on November 12, 2026, shares were little changed during the regular session and slipped roughly 1% in after-hours trading to around $6.21. The stock has been under pressure year to date, down approximately 41%, which frames a cautious investor posture heading into the print.
Sentiment appears to be balancing two competing narratives: continued slow revenue growth and a modest consensus miss on the one hand, against a materially stronger balance sheet and the long-awaited U.S. launch of AI Highlights on the other. Investors appear to be treating the quarter as transitional, with greater weight placed on forward catalysts such as the AI commercial rollout and the planned CapsoCam Colon FDA submission than on the quarter's headline financial figures.
What to Watch Going Forward
Management has indicated that the full commercial impact of AI Highlights is likely to materialize in 2027, making the near-term adoption trajectory a key focus. Investors should monitor physician onboarding, pricing trends, and whether AI-assisted review meaningfully accelerates capsule utilization and reorders among existing accounts.
A second important catalyst is the CapsoCam Colon program. The company completed enrollment and data collection for the clinical study supporting its planned FDA submission and reiterated its intention to submit before the end of 2026. Progress here is significant because the colon market represents a substantially larger addressable opportunity than the small bowel segment.
Finally, watch cost and margin dynamics. The decline in gross margin to 49% and ongoing research and development spending will influence how quickly losses narrow. With $21.8 million in cash and reduced clinical trial spending following the colon study's completion, liquidity remains a supportive factor, but sustained commercial execution will be essential to improving the company's financial trajectory.
Enhancing Research with AI Tools
In my view, tools like Tickeron’s AI Screener can help investors quickly compare medical technology names against peers using technical patterns, fundamentals, and AI-driven signals. I find it useful for generating broader ideas when tracking names like CapsoVision, especially around earnings and product launches.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CV in downward trend: price dove below 50-day moving average on November 05, 2026
CV moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend. In 13 of 15 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CV as a result. In 19 of 26 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for CV turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 5 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where CV advanced for three days, in 63 of 73 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
CV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 31 of 34 cases where CV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. CV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CV's P/B Ratio (25.542) is slightly higher than the industry average of (4.142). P/E Ratio (-5.672) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (21.598) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement